260 related articles for article (PubMed ID: 16924053)
1. Wilms tumor 1 expression present in most melanomas but nearly absent in nevi.
Perry BN; Cohen C; Govindarajan B; Cotsonis G; Arbiser JL
Arch Dermatol; 2006 Aug; 142(8):1031-4. PubMed ID: 16924053
[TBL] [Abstract][Full Text] [Related]
2. Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma.
Massi D; Naldini A; Ardinghi C; Carraro F; Franchi A; Paglierani M; Tarantini F; Ketabchi S; Cirino G; Hollenberg MD; Geppetti P; Santucci M
Hum Pathol; 2005 Jun; 36(6):676-85. PubMed ID: 16021575
[TBL] [Abstract][Full Text] [Related]
3. Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi.
Clarke LE; Fountaine TJ; Hennessy J; Bruggeman RD; Clarke JT; Mauger DT; Helm KF
J Cutan Pathol; 2009 Apr; 36(4):433-8. PubMed ID: 19278428
[TBL] [Abstract][Full Text] [Related]
4. Cyclin D1 expression in melanocytic lesions of the skin.
Ramirez JA; Guitart J; Rao MS; Diaz LK
Ann Diagn Pathol; 2005 Aug; 9(4):185-8. PubMed ID: 16084449
[TBL] [Abstract][Full Text] [Related]
5. Macrophage migration inhibitory factor protein and mRNA expression in cutaneous melanocytic tumours.
Miracco C; De Nisi MC; Arcuri F; Cosci E; Pacenti L; Toscano M; Lalinga AV; Biagioli M; Rubegni P; Vatti R; Maellaro E; Del Bello B; Massi D; Luzi P; Tosi P
Int J Oncol; 2006 Feb; 28(2):345-52. PubMed ID: 16391788
[TBL] [Abstract][Full Text] [Related]
6. G1 cell cycle regulators in congenital melanocytic nevi. Comparison with acquired nevi and melanomas.
Stefanaki C; Stefanaki K; Antoniou C; Argyrakos T; Stratigos A; Patereli A; Katsambas A
J Cutan Pathol; 2008 Sep; 35(9):799-808. PubMed ID: 18494826
[TBL] [Abstract][Full Text] [Related]
7. Nestin expression in cutaneous melanomas and melanocytic nevi.
Brychtova S; Fiuraskova M; Hlobilková A; Brychta T; Hirnak J
J Cutan Pathol; 2007 May; 34(5):370-5. PubMed ID: 17448190
[TBL] [Abstract][Full Text] [Related]
8. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
9. S100A6 protein expression is different in Spitz nevi and melanomas.
Ribé A; McNutt NS
Mod Pathol; 2003 May; 16(5):505-11. PubMed ID: 12748257
[TBL] [Abstract][Full Text] [Related]
10. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical markers for distinguishing Spitz nevi from malignant melanomas.
Kanter-Lewensohn L; Hedblad MA; Wejde J; Larsson O
Mod Pathol; 1997 Sep; 10(9):917-20. PubMed ID: 9310955
[TBL] [Abstract][Full Text] [Related]
12. Cyclooxygenase-2 (COX-2): first immunohistochemical marker distinguishing early cutaneous melanomas from benign melanocytic skin tumours.
Chwirot BW; Kuźbicki Ł
Melanoma Res; 2007 Jun; 17(3):139-45. PubMed ID: 17505259
[TBL] [Abstract][Full Text] [Related]
13. Clusterin expression in primary and metastatic melanoma.
Busam KJ; Kucukgol D; Eastlake-Wade S; Frosina D; Delgado R; Jungbluth AA
J Cutan Pathol; 2006 Sep; 33(9):619-23. PubMed ID: 16965336
[TBL] [Abstract][Full Text] [Related]
14. Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma.
Prieto VG; Mourad-Zeidan AA; Melnikova V; Johnson MM; Lopez A; Diwan AH; Lazar AJ; Shen SS; Zhang PS; Reed JA; Gershenwald JE; Raz A; Bar-Eli M
Clin Cancer Res; 2006 Nov; 12(22):6709-15. PubMed ID: 17121890
[TBL] [Abstract][Full Text] [Related]
15. Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin.
van den Oord JJ; Paemen L; Opdenakker G; de Wolf-Peeters C
Am J Pathol; 1997 Sep; 151(3):665-70. PubMed ID: 9284814
[TBL] [Abstract][Full Text] [Related]
16. Cell adhesion and communication proteins are differentially expressed in melanoma progression model.
Rezze GG; Fregnani JH; Duprat J; Landman G
Hum Pathol; 2011 Mar; 42(3):409-18. PubMed ID: 21193224
[TBL] [Abstract][Full Text] [Related]
17. Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters.
Busam KJ; Iversen K; Berwick M; Spagnoli GC; Old LJ; Jungbluth AA
Mod Pathol; 2000 Apr; 13(4):459-65. PubMed ID: 10786815
[TBL] [Abstract][Full Text] [Related]
18. Tissue microarray analysis of ezrin, KBA.62, CD166, nestin, and p-Akt in melanoma versus banal and atypical nevi, and nonmelanocytic lesions.
Shanesmith RP; Smart C; Cassarino DS
Am J Dermatopathol; 2011 Oct; 33(7):663-8. PubMed ID: 21915031
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor expression in malignant melanoma: prognostic versus diagnostic usefulness.
Bayer-Garner IB; Hough AJ; Smoller BR
Mod Pathol; 1999 Aug; 12(8):770-4. PubMed ID: 10463478
[TBL] [Abstract][Full Text] [Related]
20. WT 1 expression in nevi and melanomas: a marker of melanocytic invasion into the dermis.
Garrido-Ruiz MC; Rodriguez-Pinilla SM; Pérez-Gómez B; Rodriguez-Peralto JL
J Cutan Pathol; 2010 May; 37(5):542-8. PubMed ID: 19638168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
